Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?

Show other versions (1)

Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement. The diagnosis is stabilized by hematopoietic stem cell expressing a fusion gene...

Full description

Bibliographic Details
Main Authors:	Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2015-04-01
Series:	Reviews in Clinical Medicine
Subjects:	chronic myelogenous leukemia imatinib thyroid dysfunction
Online Access:	https://rcm.mums.ac.ir/article_4041_36c049a261ff67e6921b23458e638f27.pdf

Similar Items

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-01-01)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01)

Imatinib-Induced Psoriasis
by: Figen Atalay, et al.
Published: (2013-06-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

XML Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
by: Abolghasem Allahyari, et al.
Published: (2016-03-01)

TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
by: Mateja Grat, et al.
Published: (2004-12-01)

CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML
by: An-Ni Zhong, et al.
Published: (2021-09-01)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
by: Hamza MS, et al.
Published: (2022-05-01)

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
by: Hyacinthe Johnson-Ansah, et al.
Published: (2022-08-01)

Frequency of the BCR/ABL rearrangements and associated alterations detected by FISH during monitoring of patients taking imatinib mesylate in isolation Freqüência do rearranjo BCR/ABL e alterações associadas detectadas por FISH no monitoramento de pacientes em uso exclusivo do mesilato de imatinibe
by: Cristina B. Vendrame-Goloni, et al.
Published: (2006-06-01)

Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
by: Milva Caputo, et al.
Published: (2011-04-01)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
by: Abhilash Chandra, et al.
Published: (2020-04-01)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01)

Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib
by: Phatchanat Klaihmon, et al.
Published: (2024-02-01)

Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients
by: Ali M. Jawad, et al.
Published: (2008-10-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

Tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in CML patients
by: V. A. Shuvaev, et al.
Published: (2014-07-01)

HIF2-α Expression in CML Patients Receiving Hydroxyurea Prior to Imatinib That Achieved Major Molecular Response (MMR) versus in Those Not Achieving MMR
by: Rinaldi I, et al.
Published: (2024-02-01)

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01)

Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
by: Xiaoying Lan, et al.
Published: (2016-11-01)

Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib
by: Naveed Ali, et al.
Published: (2016-03-01)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01)

A novel case of chronic spontaneous urticaria associated chronic myelogenous leukemia with rapid resolution upon treatment with imatinib
by: Alexis Tracy, MD, et al.
Published: (2022-12-01)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Kota Yoshifuji, et al.
Published: (2022-10-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2019-10-01)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01)

PDGFR-β mediated growth failure in pediatric CML cases on Imatinib
by: Prakamya Gupta, et al.
Published: (2020-09-01)

Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia
by: Pradeep Balasubramanian, et al.
Published: (2015-01-01)

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01)

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature
by: Narender Kumar, et al.
Published: (2013-01-01)

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
by: Xin P, et al.
Published: (2017-04-01)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)

HLA Class II Allele and Haplotype Frequencies in Iranian Patients with Leukemia
by: Farideh Khosravi, et al.
Published: (2007-09-01)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
by: Olga Meltem Akay, et al.
Published: (2016-05-01)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
by: Takaaki Ono
Published: (2021-10-01)

Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01)

O tratamento da Leucemia Mielóide Crônica com mesilato de imatinibe Therapy of Chronic Myeloid Leukemia with imatinib mesylate
by: Vaneuza M. Funke, et al.
Published: (2008-04-01)

Acompanhamento farmacoterapêutico dos pacientes com leucemia mieloide crônica em uso de mesilato de imatinibe na Universidade Federal do Ceará The pharmacotherapeutic follow- up of patients with chronic myeloid leukemia (CML) on imatinib mesylate therapy
by: Sterfen S. Aquino, et al.
Published: (2009-01-01)